Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholangiocarcinoma
2011

Cancer-Testis Antigens in Intrahepatic Cholangiocarcinoma

Sample size: 89 publication Evidence: moderate

Author Information

Author(s): Zhou Jin-xue, Li Yin, Chen Sun-xiao, Deng An-mei

Primary Institution: Henan Tumor Hospital

Hypothesis

The study aims to investigate the expression of cancer-testis antigens (CTAs) in intrahepatic cholangiocarcinoma (IHCC) and evaluate their potential therapeutic values.

Conclusion

Specific immunotherapy targeted at cancer-testis antigens might be a novel treatment option for patients with intrahepatic cholangiocarcinoma.

Supporting Evidence

  • The expression rates of MAGE-A1, MAGE-A3/4, and NY-ESO-1 were 29.2%, 27.0%, and 22.5%, respectively.
  • Positive MAGE-3/4 expression correlated with larger tumor size and poor prognosis.
  • At least one CTA marker expression was identified as an independent prognostic factor in patients with IHCC.

Takeaway

The study found that some cancer cells have special markers that could help doctors create new treatments for a type of liver cancer.

Methodology

The study assessed the expression of CTAs and HLA Class I in 89 IHCC patients using immunohistochemistry.

Limitations

The study is limited to a relatively small case series.

Participant Demographics

Patients with intrahepatic cholangiocarcinoma who underwent curative resection.

Statistical Information

P-Value

0.009

Confidence Interval

0.298-0.920

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-9966-30-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication